Dataset Information

Assessing amblyopia treatment using multifocal visual evoked potentials.

ABSTRACT:

Background

To evaluate the effect of occlusion treatment for anisometropic amblyopia using multifocal visual evoked potentials (mfVEPs).

Methods

The patients for this study comprised 19 patients (mean age 6.05?±?1.65 years) with anisometropic amblyopia underwent mfVEP analysis using the RETIscan® system before and after occlusion treatment. After dividing the area into six ring areas and four quadrants, we analyzed the amplitudes and latencies of the mfVEPs.

Results

The amplitudes of ring 1 (central field) in amblyopic eyes after treatment were significantly higher than those in the other rings (p?=?0.001). The mfVEP amplitudes in each of the six rings between amblyopic eyes and fellow eyes at diagnosis and after occlusion treatment showed no significant differences. In quadrant 1 the amplitudes of the amblyopic eyes and fellow eyes were significantly different at the time of diagnosis (p?=?0.005), whereas after occlusion treatment there was no significant difference (p?=?0.888). The amplitudes for each of the six rings at diagnosis and after occlusion treatment in amblyopic eyes versus fellow eyes showed no significant difference. There were also no differences in the amplitudes in each of the four quadrants at the time of diagnosis and after occlusion treatment in amblyopic eyes versus fellow eyes. No significant difference was found in the comparison of latency values in each of the six rings or in each of the four quadrants at diagnosis and after occlusion treatment in amblyopic eyes versus their fellow eyes.

Conclusions

The amplitudes of quadrant 1 in amblyopic eyes compared with those of the fellow eyes at diagnosis were increased after occlusion treatment. Changes of the difference between amblyopic eyes and fellow eyes in quadrant 1 after occlusion treatment could be a useful, objective method for monitoring improvement in visual acuity.

SUBMITTER: Jang J

PROVIDER: S-EPMC6090668 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Assessing amblyopia treatment using multifocal visual evoked potentials.

Jang Junwon J Kyung Sungeun E SE

BMC ophthalmology 20180813 1

<h4>Background</h4>To evaluate the effect of occlusion treatment for anisometropic amblyopia using multifocal visual evoked potentials (mfVEPs).<h4>Methods</h4>The patients for this study comprised 19 patients (mean age 6.05 ± 1.65 years) with anisometropic amblyopia underwent mfVEP analysis using the RETIscan® system before and after occlusion treatment. After dividing the area into six ring areas and four quadrants, we analyzed the amplitudes and latencies of the mfVEPs.<h4>Results</h4>The amp ...[more]

PMID: 30103718

Similar Datasets

Project description:BackgroundMultifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advantages over FF-VEP as an endpoint in clinical trials of remyelinating therapies.ObjectiveMF-VEP testing was used to study changes in visual pathways in 48% of RENEW [phase II, opicinumab (anti-LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants.MethodsThis exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants in the intent-to-treat (ITT; n = 39; 72% female; mean age: 32.3 years) and per-protocol (PP; n = 31; 71% female; mean age: 32.2 years) populations in affected and fellow eye latency from fellow eye baseline latency and affected and fellow eye amplitude from their own baselines. Treatment differences were evaluated using analysis of covariance (week 24) and a mixed-effect model of repeated measures (week 32). Last observation carried forward was used to impute missing data at week 24.ResultsA trend for improvement in affected eye MF-VEP latency with opicinumab versus placebo was seen in the ITT and PP populations at weeks 24 and 32. Both treatment groups in the ITT population experienced partial recovery of amplitude in the affected eye at week 32. Notably, the mean change in fellow eye amplitude at weeks 24 and 32 was - 17.57 and - 31.41 nanovolts (nV) in placebo but only - 0.59 and 1.93 nV in the opicinumab group [differences at weeks 24 and 32: 16.98 nV (p = 0.050) and 33.33 nV (p < 0.01), respectively].ConclusionResults from this substudy showed advantages of MF-VEP over FF-VEP in multicenter studies of central nervous system reparative therapies and provide novel evidence that fellow eye visual pathway amplitude loss occurs after optic neuritis but can potentially be prevented by opicinumab treatment.RegistrationClinicalTrials.gov identifier NCT01721161.

Dataset Information

Assessing amblyopia treatment using multifocal visual evoked potentials.

Background

Methods

Results

Conclusions

Publications

Assessing amblyopia treatment using multifocal visual evoked potentials.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets